Development of novel vaccine vectors: Chimpanzee adenoviral vectors

References

• Cheng C, Wang L, Ko SY, Kong WP, Schmidt SD, Gall JGD, Colloca S, Seder RA, Mascola JR, Nabel GJ. Combination recombinant simian or chimpanzee adenoviral vectors for vaccine development. Vaccine. 2015;33:7344–7351. doi:10.1016/j.vaccine.2015.10.023. PMID:26514419.
   PubMed Web of Science ®Google Scholar
• Zhang C, Chi Y, Zhou D. Development of Novel vaccines against infectious diseases based on chimpanzee adenoviral vector. Methods Mol Biol. 2017;1581:3–13. doi:10.1007/978-1-4939-6869-5_1. PMID:28374240.
   PubMedGoogle Scholar
• Alonso-Padilla J, Papp T, Kajan GL, Benko M, Havenga M, Lemckert A, Harrach B, Baker AH. Development of novel Adenoviral vectors to overcome challenges observed with HAdV-5-based constructs. Mol Ther. 2016;24:6–16. doi:10.1038/mt.2015.194. PMID:26478249.
   PubMed Web of Science ®Google Scholar
• Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, Holterman L, Damen I, Vogels R, Thorner AR, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81:4654–4663. doi:10.1128/JVI.02696-06. PMID:17329340.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, Costner P, Desai N, Holman L, Enama ME, Yamshchikov G, Mulangu S, Hu Z, Andrews CA, Sheets RA, et al. A replication defective recombinant Ad5 vaccine expressing Ebola virus GP is safe and immunogenic in healthy adults. Vaccine. 2010;29:304–313. doi:10.1016/j.vaccine.2010.10.037. PMID:21034824.
   PubMed Web of Science ®Google Scholar
• Peruzzi D, Dharmapuri S, Cirillo A, Bruni BE, Nicosia A, Cortese R, Colloca S, Ciliberto G, La Monica N, Aurisicchio L. A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine. 2009;27:1293–1300. doi:10.1016/j.vaccine.2008.12.051. PMID:19162112.
   PubMed Web of Science ®Google Scholar
• Mast TC, Kierstead L, Gupta SB, Nikas AA, Kallas EG, Novitsky V, Mbewe B, Pitisuttithum P, Schechter M, Vardas E, et al. International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials. Vaccine. 2010;28:950–957. doi:10.1016/j.vaccine.2009.10.145. PMID:19925902.
   PubMed Web of Science ®Google Scholar
• Wang X, Xing M, Zhang C, Yang Y, Chi Y, Tang X, Zhang H, Xiong S, Yu L, Zhou D. Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China. Emerg Microbes Infect. 2014;3: e30. doi:10.1038/emi.2014.30. PMID:26038738.
   PubMed Web of Science ®Google Scholar
• Tatsis N, Tesema L, Robinson ER, Giles-Davis W, McCoy K, Gao GP, Wilson JM, Ertl HC. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 2006;13:421–429. doi:10.1038/sj.gt.3302675. PMID:16319951.
   PubMed Web of Science ®Google Scholar
• Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, Cirillo A, Siani L, Naddeo M, Grazioli F, Esposito ML, et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med. 2012;4:115ra112. doi:10.1126/scitranslmed.3002925.
   Web of Science ®Google Scholar
• Capone S, D'Alise AM, Ammendola V, Colloca S, Cortese R, Nicosia A, Folgori A. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials. Expert Rev Vaccines. 2013;12:379–393. doi:10.1586/erv.13.15. PMID:23560919.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Li Y, Cun A, Yang W, Ellenberg S, Switzer WM, Kalish ML, Ertl HC. Chimpanzee adenovirus antibodies in humans, sub-Saharan Africa. Emerg Infect Dis. 2006;12:1596–1599. doi:10.3201/eid1210.060078. PMID:17176582.
   PubMed Web of Science ®Google Scholar
• Xiang Z, Gao G, Reyes-Sandoval A, Cohen CJ, Li Y, Bergelson JM, Wilson JM, Ertl HC. Novel, chimpanzee serotype 68-based adenoviral vaccine carrier for induction of antibodies to a transgene product. J Virol. 2002;76:2667–2675. doi:10.1128/JVI.76.6.2667-2675.2002. PMID:11861833.
   PubMed Web of Science ®Google Scholar
• Quinn KM, Da Costa A, Yamamoto A, Berry D, Lindsay RW, Darrah PA, Wang L, Cheng C, Kong WP, Gall JG, et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol. 2013;190:2720–2735. doi:10.4049/jimmunol.1202861. PMID:23390298.
   PubMed Web of Science ®Google Scholar
• Ledgerwood JE, DeZure AD, Stanley DA, Coates EE, Novik L, Enama ME, Berkowitz NM, Hu Z, Joshi G, Ploquin A, et al. Chimpanzee Adenovirus Vector Ebola Vaccine. N Engl J Med. 2017;376:928–938. doi:10.1056/NEJMoa1410863. PMID:25426834.
   PubMed Web of Science ®Google Scholar
• Fitzgerald JC, Gao GP, Reyes-Sandoval A, Pavlakis GN, Xiang ZQ, Wlazlo AP, Giles-Davis W, Wilson JM, Ertl HC. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag. J Immunol. 2003;170:1416–1422. doi:10.4049/jimmunol.170.3.1416. PMID:12538702.
   PubMed Web of Science ®Google Scholar
• Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20:1126–1129. PMID:25194571.
   PubMed Web of Science ®Google Scholar
• Roy S, Vandenberghe LH, Kryazhimskiy S, Grant R, Calcedo R, Yuan X, Keough M, Sandhu A, Wang Q, Medina-Jaszek CA, et al. Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathog. 2009;5:e1000503. doi:10.1371/journal.ppat.1000503. PMID:19578438.
   PubMed Web of Science ®Google Scholar
• Chen EC, Yagi S, Kelly KR, Mendoza SP, Tarara RP, Canfield DR, Maninger N, Rosenthal A, Spinner A, Bales KL, et al. Cross-species transmission of a novel adenovirus associated with a fulminant pneumonia outbreak in a new world monkey colony. PLoS Pathog. 2011;7:e1002155. doi:10.1371/journal.ppat.1002155. PMID:21779173.
   PubMed Web of Science ®Google Scholar
• Graham FL, Smiley J, Russell WC, Nairn R. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977;36:59–74. doi:10.1099/0022-1317-36-1-59. PMID:886304.
   PubMed Web of Science ®Google Scholar
• Fallaux FJ, Kranenburg O, Cramer SJ, Houweling A, Van Ormondt H, Hoeben RC, Van Der Eb AJ. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. Hum Gene Ther. 1996;7:215–222. doi:10.1089/hum.1996.7.2-215. PMID:8788172.
   PubMed Web of Science ®Google Scholar
• Chen XG, Lv QX, Zhou XQ. Construction of recombinant adenovirus Ad-rat PLCg2-shRNA and successful suppression of PLCg2 expression in BRL-3A cells. Genet Mol Res. 2016;15:1–10
   Web of Science ®Google Scholar
• Luo J, Deng ZL, Luo X, Tang N, Song WX, Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2007;2:1236–1247. doi:10.1038/nprot.2007.135. PMID:17546019.
   PubMed Web of Science ®Google Scholar
• He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A. 1998;95:2509–2514. doi:10.1073/pnas.95.5.2509. PMID:9482916.
   PubMed Web of Science ®Google Scholar
• Hoffmann D, Wildner O. Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coli. BMC Biotechnol. 2006;6:36. doi:10.1186/1472-6750-6-36. PMID:16887042.
   PubMed Web of Science ®Google Scholar
• Chartier C, Degryse E, Gantzer M, Dieterle A, Pavirani A, Mehtali M. Efficient generation of recombinant adenovirus vectors by homologous recombination in Escherichia coli. J Virol. 1996;70:4805–4810. PMID:8676512.
   PubMed Web of Science ®Google Scholar
• Zhou D, Zhou X, Bian A, Li H, Chen H, Small JC, Li Y, Giles-Davis W, Xiang Z, Ertl HCJ. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc. 2010;5:1775–1785. doi:10.1038/nprot.2010.134. PMID:21030953.
   PubMed Web of Science ®Google Scholar
• Yang Y, Chi Y, Tang X, Ertl HCJ, Zhou D. Rapid, efficient, and modular generation of adenoviral vectors via isothermal assembly. Hoboken, NJ, USA: John Wiley & Sons, Inc. 2016: 16.26.11-16.26.18.
   Google Scholar
• Gibson DG, Benders GA, Andrews-Pfannkoch C, Denisova EA, Baden-Tillson H, Zaveri J, Stockwell TB, Brownley A, Thomas DW, Algire MA, et al. Complete chemical synthesis, assembly, and cloning of a Mycoplasma genitalium genome. Science. 2008;319:1215–1220. doi:10.1126/science.1151721. PMID:18218864.
   PubMed Web of Science ®Google Scholar
• Gibson DG, Glass JI, Lartigue C, Noskov VN, Chuang RY, Algire MA, Benders GA, Montague MG, Ma L, Moodie MM, et al. Creation of a bacterial cell controlled by a chemically synthesized genome. Science. 2010;329:52–56. doi:10.1126/science.1190719. PMID:20488990.
   PubMed Web of Science ®Google Scholar
• Gibson DG. Enzymatic assembly of overlapping DNA fragments. Methods Enzymol. 2011;498:349–361. doi:10.1016/B978-0-12-385120-8.00015-2. PMID:21601685.
   PubMed Web of Science ®Google Scholar
• Gu L, Krendelchtchikova V, Krendelchtchikov A, Farrow AL, Derdeyn CA, Matthews QL. Adenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via “Antigen Capsid-Incorporation” strategy. Virology. 2016;487:75–84. doi:10.1016/j.virol.2015.10.010. PMID:26499044.
   PubMed Web of Science ®Google Scholar
• Tian X, Su X, Li X, Li H, Li T, Zhou Z, Zhong T, Zhou R. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon. PLoS One. 2012;7:e41381. doi:10.1371/journal.pone.0041381. PMID:22848478.
   PubMed Web of Science ®Google Scholar
• Farrow AL, Rachakonda G, Gu L, Krendelchtchikova V, Nde PN, Pratap S, Lima MF, Villalta F, Matthews QL. Immunization with Hexon modified adenoviral vectors integrated with gp83 epitope provides protection against Trypanosoma cruzi infection. PLoS Negl Trop Dis. 2014;8:e3089. doi:10.1371/journal.pntd.0003089. PMID:25144771.
   PubMed Web of Science ®Google Scholar
• Matthews QL, Farrow AL, Rachakonda G, Gu L, Nde P, Krendelchtchikov A, Pratap S, Sakhare SS, Sabbaj S, Lima MF, Villalta F. Epitope capsid-incorporation: new effective approach for vaccine development for chagas disease. Pathog Immun. 2016;1:214–233. doi:10.20411/pai.v1i2.114. PMID:27709126.
   PubMedGoogle Scholar
• Zhou D, Cun A, Li Y, Xiang Z, Ertl HC. A chimpanzee-origin adenovirus vector expressing the rabies virus glycoprotein as an oral vaccine against inhalation infection with rabies virus. Mol Ther. 2006;14:662–672. doi:10.1016/j.ymthe.2006.03.027. PMID:16797238.
   PubMed Web of Science ®Google Scholar
• Zhi Y, Figueredo J, Kobinger GP, Hagan H, Calcedo R, Miller JR, Gao G, Wilson JM. Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther. 2006;17:500–506. doi:10.1089/hum.2006.17.500. PMID:16716107.
   PubMed Web of Science ®Google Scholar
• Tapia MD, Sow SO, Lyke KE, Haidara FC, Diallo F, Doumbia M, Traore A, Coulibaly F, Kodio M, Onwuchekwa U, et al. Use of ChAd3-EBO-Z Ebola virus vaccine in Malian and US adults, and boosting of Malian adults with MVA-BN-Filo: a phase 1, single-blind, randomised trial, a phase 1b, open-label and double-blind, dose-escalation trial, and a nested, randomised, double-blind, placebo-controlled trial. Lancet Infect Dis. 2016;16:31–42. doi:10.1016/S1473-3099(15)00362-X. PMID:26546548.
   PubMed Web of Science ®Google Scholar
• De Santis O, Audran R, Pothin E, Warpelin-Decrausaz L, Vallotton L, Wuerzner G, Cochet C, Estoppey D, Steiner-Monard V, Lonchampt S, et al. Safety and immunogenicity of a chimpanzee adenovirus-vectored Ebola vaccine in healthy adults: a randomised, double-blind, placebo-controlled, dose-finding, phase 1/2a study. Lancet Infect Dis. 2016;16:311–320. doi:10.1016/S1473-3099(15)00486-7. PMID:26725450.
   PubMed Web of Science ®Google Scholar
• Stanley DA, Honko AN, Asiedu C, Trefry JC, Lau-Kilby AW, Johnson JC, Hensley L, Ammendola V, Abbate A, Grazioli F, et al. Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge. Nat Med. 2014;20:1126–1129. PMID:25194571.
   PubMed Web of Science ®Google Scholar
• Ewer K, Rampling T, Venkatraman N, Bowyer G, Wright D, Lambe T, Imoukhuede EB, Payne R, Fehling SK, Strecker T, et al. A Monovalent Chimpanzee Adenovirus Ebola Vaccine Boosted with MVA. N Engl J Med. 2016;374:1635–1646. doi:10.1056/NEJMoa1411627. PMID:25629663.
   PubMed Web of Science ®Google Scholar
• Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, Eckes R, Feinberg M, Follmann D, Grund B, et al. Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia. N Engl J Med. 2017;377:1438–1447. doi:10.1056/NEJMoa1614067. PMID:29020589.
   PubMed Web of Science ®Google Scholar
• Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, Halstead FD, Ewer KJ, Mahungu T, Spencer AJ, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012;7:e31208. doi:10.1371/journal.pone.0031208. PMID:22363582.
   PubMed Web of Science ®Google Scholar
• Rampling T, Ewer KJ, Bowyer G, Bliss CM, Edwards NJ, Wright D, Payne RO, Venkatraman N, de Barra E, Snudden CM, et al. Safety and high level efficacy of the combination malaria vaccine regimen of RTS,S/AS01B with chimpanzee adenovirus 63 and modified vaccinia ankara vectored vaccines expressing ME-TRAP. J Infect Dis. 2016;214:772–781. doi:10.1093/infdis/jiw244. PMID:27307573.
   PubMed Web of Science ®Google Scholar
• Hayton EJ, Rose A, Ibrahimsa U, Del Sorbo M, Capone S, Crook A, Black AP, Dorrell L, Hanke T. Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One. 2014;9:e101591. doi:10.1371/journal.pone.0101591. PMID:25007091.
   PubMed Web of Science ®Google Scholar
• Barnes E, Folgori A, Capone S, Swadling L, Aston S, Kurioka A, Meyer J, Huddart R, Smith K, Townsend R, et al. Novel adenovirus-based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med. 2012;4:115ra111. doi:10.1126/scitranslmed.3003155.
   Web of Science ®Google Scholar
• Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, Cortese R, Thompson AJ, Sande CS, de Lara C, et al. Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open. 2015;5:e008748. doi:10.1136/bmjopen-2015-008748. PMID:26510727.
   PubMed Web of Science ®Google Scholar
• Georgiades J, Zaremba W. Comparative investigations of the behaviour of the aldolase test, urobilinogenuria test and the colloid oscillation test on the blood serum of persons from the environment of patients affected with hepatitis epidemica. Biul Inst Med Morsk Gdansk. 1959;10:59–63. PMID:13827366.
   PubMedGoogle Scholar
• Lichtenstein DL, Wold WS. Experimental infections of humans with wild-type adenoviruses and with replication-competent adenovirus vectors: replication, safety, and transmission. Cancer Gene Ther. 2004;11:819–829. doi:10.1038/sj.cgt.7700765. PMID:15359291.
   PubMed Web of Science ®Google Scholar
• Field's Virology. Philadelphia: Lippincott Williams & Wilkins; 2007.
   Google Scholar
• Chirmule N, Propert K, Magosin S, Qian Y, Qian R, Wilson J. Immune responses to adenovirus and adeno-associated virus in humans. Gene Ther 1999, 6:1574–1583. doi:10.1038/sj.gt.3300994. PMID:10490767.
   PubMed Web of Science ®Google Scholar
• Farina SF, Gao GP, Xiang ZQ, Rux JJ, Burnett RM, Alvira MR, Marsh J, Ertl HC, Wilson JM. Replication-defective vector based on a chimpanzee adenovirus. J Virol. 2001;75:11603–11613. doi:10.1128/JVI.75.23.11603-11613.2001. PMID:11689642.
   PubMed Web of Science ®Google Scholar
• Cheng T, Song Y, Zhang Y, Zhang C, Yin J, Chi Y, Zhou D. A novel oncolytic adenovirus based on simian adenovirus serotype 24. Oncotarget. 2017;8:26871–26885. PMID:28460470.
   PubMed Web of Science ®Google Scholar
• Belousova N, Mikheeva G, Xiong C, Soghomonian S, Young D, Le Roux L, Naff K, Bidaut L, Wei W, Li C, et al. Development of a targeted gene vector platform based on simian adenovirus serotype 24. J Virol. 2010;84:10087–10101. doi:10.1128/JVI.02425-09. PMID:20631120.
   PubMed Web of Science ®Google Scholar
• Behr M, Kaufmann JK, Ketzer P, Engelhardt S, Muck-Hausl M, Okun PM, Petersen G, Neipel F, Hassel JC, Ehrhardt A, et al. Adenoviruses using the cancer marker EphA2 as a receptor in vitro and in vivo by genetic ligand insertion into different capsid scaffolds. PLoS One. 2014;9:e95723. doi:10.1371/journal.pone.0095723. PMID:24760010.
   PubMed Web of Science ®Google Scholar
• Jin C, Yu D, Cancer M, Nilsson B, Leja J, Essand M. Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy. Hum Gene Ther. 2013;24:766–775. doi:10.1089/hum.2012.132. PMID:23889332.
   PubMed Web of Science ®Google Scholar
• Xing M, Wang X, Chi Y, Zhou D. Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab. Oncotarget. 2016;7:28262–28272. doi:10.18632/oncotarget.8596. PMID:27058423.
   PubMed Web of Science ®Google Scholar
• Bakker JM, Bleeker WK, Parren PW. Therapeutic antibody gene transfer: an active approach to passive immunity. Mol Ther. 2004;10:411–416. doi:10.1016/j.ymthe.2004.06.865. PMID:15336642.
   PubMed Web of Science ®Google Scholar